Related Experiment Video
Updated: May 24, 2025

00:15
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
5.9K
Interactions between pathological and functional amyloid: A match made in Heaven or Hell?
Daniel E Otzen1, Samuel Peña-Díaz1, Jeremias Widmann1
1Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark.
Molecular Aspects of Medicine
|March 2, 2025
Summary
Amyloid proteins, both pathological human amyloid (PaHA) and functional bacterial amyloid (FuBA), interact in the human body, influencing disease progression. Understanding these FuBA-PaHA interactions is key to developing new therapeutic strategies for amyloid diseases.
Area of Science:
- Biochemistry
- Microbiology
- Neuroscience
Background:
- Amyloid proteins exist in pathological (neurodegenerative diseases) and functional (bacterial biofilms) forms.
- The human body hosts pathological human amyloid (PaHA), functional bacterial amyloid (FuBA) from the microbiome, and dietary amyloid.
- Amyloid fragments can propagate pathological forms and cross-seed dissimilar sequences, with FuBA-PaHA interactions increasingly implicated in vivo.
Purpose of the Study:
- To understand the structural and bioinformatic basis of cross-talk between FuBA and PaHA.
- To investigate the mechanisms of FuBA-PaHA interactions, including cross-stimulation and inhibition.
- To explore the role of these interactions in the transmission and development of neurodegenerative diseases.
Main Methods:
- Utilized atomic-level structures of bacterial amyloids CsgA and FapC.
- Performed in vitro and in vivo experiments to study FuBA-PaHA interactions.
- Employed computational methods to analyze sequence and structure relationships and chaperone activity.
Main Results:
- Uncovered significant cross-stimulation and inhibition between FuBA and PaHA, despite limited sequence homology.
- Demonstrated that FuBA and PaHA can interact via the gut-brain axis, influencing aggregation and inflammation.
- Showed that microbiome chaperones can recognize and inhibit both FuBA and PaHA growth.
Conclusions:
- Heterotypic interactions between FuBA and PaHA are a vital aspect of the amyloid phenomenon.
- These interactions have significant implications for neurodegenerative disease development and transmission.
- Further research into FuBA-PaHA interactions offers a vibrant frontier for understanding and treating amyloid-related conditions.
Related Concept Videos
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145

